Nasdaq · Healthcare
ImmunityBio, Inc. (IBRX)
As-reported financials and recent SEC filings for ImmunityBio, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$113.3M
Net income
$-351.4M
Net margin
—
Diluted EPS
$-0.38
ROE
70.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 |
| Gross profit | — | — | — | — | — |
| Operating income | $-256.0M | $-344.2M | $-362.3M | $-351.3M | $-330.3M |
| Net income | $-351.4M | $-413.6M | $-583.2M | $-416.6M | $-346.8M |
| Diluted EPS | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →42026-07-06
View on EDGAR →1442026-07-02
View on EDGAR →1442026-07-01
View on EDGAR →42026-07-01
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-29
View on EDGAR →42026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on IBRX
Search ImmunityBio, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.